Therapeutic strategies to target connective tissue growth factor in fibrotic lung diseases

被引：22

作者：

Isshiki, Takuma ^{[1
,2
,3
]}

Naiel, Safaa ^{[1
,2
]}

Vierhout, Megan ^{[1
,2
]}

Otsubo, Kohei ^{[1
,4
]}

Ali, Pareesa ^{[1
,2
]}

Tsubouchi, Kazuya ^{[1
,4
]}

Yazdanshenas, Parichehr ^{[1
,2
]}

Kumaran, Vaishnavi ^{[1
,2
]}

Dvorkin-Gheva, Anna ^{[2
]}

Kolb, Martin R. J. ^{[1
]}

Ask, Kjetil ^{[1
,2
,5
,6
]}

机构：

[1] McMaster Univ, Firestone Inst Resp Hlth, Dept Med, 5o Charlton Ave East, Hamilton, ON L8N 4A6, Canada

[2] McMaster Univ, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, 1280 Main St West, Hamilton, ON L8S 48L, Canada

[3] Toho Univ, Dept Resp Med, Sch Med, 6-11-1 Omori Nisi,Ota ku, Tokyo 1438541, Japan

[4] Kyushu Univ, Res Inst Dis Chest, Grad Sch Med Sci, 3-1-1 Maidashi,Higashi Ku, Fukuoka 8128582, Japan

[5] McMaster Univ, Dept Med, Luke Wing,Rm L314-5,50 Charlton Ave East, Hamilton, ON L8N 4A6, Canada

[6] Firestone Inst Resp Hlth, Res Inst St Joes Hamilton, Luke Wing,Rm L314-5,50 Charlton Ave East, Hamilton, ON L8N 4A6, Canada

来源：

PHARMACOLOGY & THERAPEUTICS | 2024年 / 253卷

关键词：

CTGF; Interstitial pneumonia; IPF; Pulmonary fibrosis; Therapeutics; IDIOPATHIC PULMONARY-FIBROSIS; ALVEOLAR EPITHELIAL-CELLS; C-TERMINAL DOMAIN; CCN2; EXPRESSION; GENE-PRODUCT; FACTOR CTGF; I COLLAGEN; STEM-CELLS; TGF-BETA; FIBROBLASTS;

D O I：

10.1016/j.pharmthera.2023.108578

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The treatment of interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF), remains challenging as current available antifibrotic agents are not effective in halting disease progression. Connective tissue growth factor (CTGF), also known as cellular communication factor 2 (CCN2), is a member of the CCN family of proteins that regulates cell signaling through cell surface receptors such as integrins, the activity of cytokines/growth factors, and the turnover of extracellular matrix (ECM) proteins. Accumulating evidence indicates that CTGF plays a crucial role in promoting lung fibrosis through multiple processes, including inducing transdifferentiation of fibroblasts to myofibroblasts, epithelial-mesenchymal transition (EMT), and cooperating with other fibrotic mediators such as TGF-beta. Increased expression of CTGF has been observed in fibrotic lungs and inhibiting CTGF signaling has been shown to suppress lung fibrosis in several animal models. Thus, the CTGF signaling pathway is emerging as a potential therapeutic target in IPF and other pulmonary fibrotic conditions. This review provides a comprehensive overview of the current evidence on the pathogenic role of CTGF in pulmonary fibrosis and discusses the current therapeutic agents targeting CTGF using a systematic review approach. (c) 2023 Elsevier Inc. All rights reserved.

引用

页数：13